MNPR compared with DRUG: revenue, margins and what each company keeps, and the suppliers and customers both name

AMNPRMonopar Therapeutics

BDRUGBright Minds Biosciences Inc.

Compare

AMNPRMonopar Therapeutics

vsBDRUGBright Minds Biosciences Inc.

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

Supply-chain overlap

News Companies A–Z Methodology Sources Corrections Terms

Not investment advice. Not a broker-dealer. Prices: Intrinio (indices shown as ETF proxies). Supply-chain data CC BY 4.0; market data not redistributable.

Desk News Calendar Saved

AMNPRMonopar Therapeutics

79.41▲+0.58%

BDRUGBright Minds Biosciences Inc.

54.56▲+0.93%

Regular sessionOct 12 '26

Compare

AMNPRMonopar Therapeutics

79.41▲+0.58%

vsBDRUGBright Minds Biosciences Inc.

54.56▲+0.93%

Regular sessionOct 12 '26

AMNPR79.41▲+0.58%vsBDRUG54.56▲+0.93%Regular sessionOct 12 '26

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

AOnly MNPR 2

AZNAstraZenecasupplier

—NorthStarunlistedsupplier

Shared 0

No shared counterparties.

BOnly DRUG 12

—Board of Trustees of the University of Illinoisunlistedsupplier

—Gerep Realty Corp.unlistedsupplier

—Technology Innovation Center LLCunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—ZoE Life Fulton Labs Incubator, LLCunlistedsupplier

8 more · DRUG chain ›

Revenue flow

latest quarter · % of own revenueMethod ›

latest quarter · % of own revenue

MNPR: latest quarter not drawable. DRUG: latest quarter not drawable.